Date: 2018-05-15
Type of information: Nomination
Compound: chief scientific officer
Company: Lysogene (France)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 15, 2018, Lysogene announced the nomination of Dr Ralph Laufer as Chief Scientific Officer and member of the executive team. Dr Ralph Laufer brings over 25 years of industry experience in drug discovery, translational research
and drug development at large pharmaceutical and biotechnology companies. Before joining Lysogene, Dr Ralph Laufer was Senior Vice President at Teva Pharmaceutical Industries in Israel, where he managed small molecule discovery, nonclinical development and CMC, leading a
team of over 400 scientists in 5 global sites. Prior to that, he was the Scientific Director of IRBM Science Park, a drug discovery CRO and biotech company in Rome, Italy.
- Previously, Dr Laufer was Head of Pharmacology at IRBM-Merck Research Laboratories Rome. He is the recipient of the
American Chemical Society 2013 Heroes of Chemistry Award for his role in the discovery of Isentress™ (raltegravir), the first integrase inhibitor approved for use in HIV infected patients. Dr Ralph Laufer originally trained as a molecular neurobiologist and his scientific achievements include the discovery of the tachykinin NK-3 receptor and the anti-obesity activity of ciliary neurotrophic factor. He is the
author of about 90 scientific articles and inventor of about 20 patents. Dr Ralph Laufer obtained his PhD in Biochemistry (summa cum laude) and M.Sc. in Chemistry from the
Hebrew University of Jerusalem. He conducted postdoctoral training at the Institut Pasteur in Paris.
Financial terms:
Latest news:
Is general: Yes
